← Back to search

Protein Structures and Oligomeric States

Enter a protein name, UniProt accession or PDB ID. Name searches ask you to confirm the protein identity before related structures are queried.

Current Protein Identity：P36544 New Search
45PDB entries
45Biological assembly
309chain/assembly records
Main Difference Dimensions in This Set
Different construct Different mutation/modification Different assembly state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics

Difference tags compare only the current result set; every original PDB and assembly record remains separate.

Related-Structure Differences

Each row represents one biological assembly in one PDB entry; multiple monomers of the same protein are listed separately.

PDB Entry Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Experimental Method Experimental Conditions Structure Quality
2MAW NMR structures of the alpha7 nAChR transmembrane domain. Deposited 2013-07-19 Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count
Chain A 228–326（99 aa） Fragment：UNP residues 141-235, transmembrane domain
Chain A 467–496（30 aa） Fragment：UNP residues 141-235, transmembrane domain
Mutation：A195S, V200S, L202S Mutation：A195S, V200S, L202S No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 0.01；Pressure ambient
NMR sample composition 0.25 mM [U-100% 13C; U-100% 15N] protein, 95% H2O/5% D2O | 95% H2O/5% D2O
Resolution not provided
7EKI human alpha 7 nicotinic acetylcholine receptor in apo-form Deposited 2021-04-05 Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 CLR CHOLESTEROL × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.18 Å
7EKP human alpha 7 nicotinic acetylcholine receptor bound to EVP-6124 Deposited 2021-04-06 Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded I33 7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 CLR CHOLESTEROL × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.85 Å
7EKT human alpha 7 nicotinic acetylcholine receptor bound to EVP-6124 and PNU-120596 Deposited 2021-04-06 Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 CLR CHOLESTEROL × 5 I33 7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide × 5 I34 N-(5-Chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.02 Å
7KOO Alpha-7 nicotinic acetylcholine receptor bound to alpha-bungarotoxin in a resting state Deposited 2020-11-09 Assembly 1 Insufficient information Heteromer；Protein × 10 PDB declaration: decameric（10） Consistent with protein count
Chain A 24–371（348 aa）
Chain A 407–502（96 aa）
Chain B 24–371（348 aa）
Chain B 407–502（96 aa）
Chain C 24–371（348 aa）
Chain C 407–502（96 aa）
Chain D 24–371（348 aa）
Chain D 407–502（96 aa）
Chain E 24–371（348 aa）
Chain E 407–502（96 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 CA CALCIUM ION × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.00 Å
7KOQ Alpha-7 nicotinic acetylcholine receptor bound to epibatidine in a desensitized state Deposited 2020-11-09 Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 24–371（348 aa）
Chain A 407–502（96 aa）
Chain B 24–371（348 aa）
Chain B 407–502（96 aa）
Chain C 24–371（348 aa）
Chain C 407–502（96 aa）
Chain D 24–371（348 aa）
Chain D 407–502（96 aa）
Chain E 24–371（348 aa）
Chain E 407–502（96 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 EPJ EPIBATIDINE × 5 CA CALCIUM ION × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.60 Å
7KOX Alpha-7 nicotinic acetylcholine receptor bound to epibatidine and PNU-120596 in the activated state Deposited 2020-11-10 Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 24–371（348 aa）
Chain A 407–502（96 aa）
Chain B 24–371（348 aa）
Chain B 407–502（96 aa）
Chain C 24–371（348 aa）
Chain C 407–502（96 aa）
Chain D 24–371（348 aa）
Chain D 407–502（96 aa）
Chain E 24–371（348 aa）
Chain E 407–502（96 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 EPJ EPIBATIDINE × 5 CA CALCIUM ION × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.70 Å
7RPM Structures of the Intracellular Domain and Transmembrane Domain of the Human alpha7 Nicotinic Acetylcholine Receptors Deposited 2021-08-03 Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 231–496（266 aa） Fragment：Transmembrane domain and intracellular domain residues 231-496
Chain B 231–496（266 aa） Fragment：Transmembrane domain and intracellular domain residues 231-496
Chain C 231–496（266 aa） Fragment：Transmembrane domain and intracellular domain residues 231-496
Chain D 231–496（266 aa） Fragment：Transmembrane domain and intracellular domain residues 231-496
Chain E 231–496（266 aa） Fragment：Transmembrane domain and intracellular domain residues 231-496
Mutation：A263S, V268S, L270S, A474E Mutation：A263S, V268S, L270S, A474E Mutation：A263S, V268S, L270S, A474E Mutation：A263S, V268S, L270S, A474E Mutation：A263S, V268S, L270S, A474E No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；308 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；308 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；308 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；308 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；308 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；308 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；298 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；298 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；298 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；298 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR sample composition 0.24 mM [U-13C; U-15N] alpha7nAChR TMD+ICD, 5 mM sodium acetate, 66 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] S358C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] C375-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 66 mM LDAO, 20 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.22 mM [U-15N] C390-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 53 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] L415C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] C427-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] C435-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.28 mM V311C-MTSL alpha7 TMD-ICD, 0.07 mM [U-15N] V311C alpha7 TMD-ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.24 mM C427-MTSL alpha7 TMD-ICD, 0.06 mM [U-15N] C427 alpha7 TMD-ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.28 mM V311C alpha7 TMD-ICD, 0.07 mM [U-15N] V311C-MTSL alpha7 TMD-ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.24 mM C427 alpha7 TMD-ICD, 0.06 mM [U-15N] C427-MTSL alpha7 TMD-ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-13C; U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] C427-EDTA-Lu3+ alpha7 TMD-ICD, 5 mM sodium acetate, 53 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.2 mM [U-15N] C427-EDTA-Tm3+ alpha7 TMD-ICD, 5 mM sodium acetate, 66 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] C317-EDTA-Lu3+ alpha7 TMD-ICD, 5 mM sodium acetate, 66 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] C317-EDTA-Tm3+ alpha7 TMD-ICD, 5 mM sodium acetate, 53 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.24 mM [U-15N] C219-EDTA-Lu3+ alpha7 TMD-ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.22 mM [U-15N] C219-EDTA-Tm3+ alpha7 TMD-ICD, 5 mM sodium acetate, 53 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.35 mM [U-13C; U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-13C; U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.35 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 66 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.22 mM [U-15N] V311C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.22 mM [U-15N] C317-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.3 mM [U-15N] C335-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 53 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.3 mM [U-15N] C342-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 66 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.3 mM [U-15N] S350C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 53 mM LDAO, 25 mM NaCl, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
Resolution not provided
8C9X human alpha7 nicotinic receptor in complex with the C4 nanobody Deposited 2023-01-23 Assembly 1 Other combination Heteromer；Protein × 10 PDB declaration: decameric（10） Consistent with protein count
Chain A 24–347（324 aa）
Chain A 455–502（48 aa）
Chain B 24–347（324 aa）
Chain B 455–502（48 aa）
Chain C 24–347（324 aa）
Chain C 455–502（48 aa）
Chain D 24–347（324 aa）
Chain D 455–502（48 aa）
Chain E 24–347（324 aa）
Chain E 455–502（48 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.30 Å
8CAU human alpha7 nicotinic receptor in complex with the C4 nanobody and nicotine Deposited 2023-01-24 Assembly 1 Other combination Heteromer；Protein × 10 PDB declaration: decameric（10） Consistent with protein count
Chain A 24–502（479 aa）
Chain B 24–502（479 aa）
Chain C 24–502（479 aa）
Chain D 24–502（479 aa）
Chain E 24–502（479 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.40 Å
8CE4 Human alpha7 nicotinic receptor in complex with the E3 nanobody Deposited 2023-02-01 Assembly 1 Other combination Heteromer；Protein × 10 PDB declaration: decameric（10） Consistent with protein count
Chain A 24–347（324 aa）
Chain A 455–502（48 aa）
Chain B 24–347（324 aa）
Chain B 455–502（48 aa）
Chain C 24–347（324 aa）
Chain C 455–502（48 aa）
Chain D 24–347（324 aa）
Chain D 455–502（48 aa）
Chain E 24–347（324 aa）
Chain E 455–502（48 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.70 Å
8CI1 Human alpha7 nicotinic receptor in complex with the E3 nanobody and nicotine Deposited 2023-02-08 Assembly 1 Other combination Heteromer；Protein × 10 PDB declaration: decameric（10） Consistent with protein count
Chain A 24–347（324 aa）
Chain A 455–502（48 aa）
Chain B 24–347（324 aa）
Chain B 455–502（48 aa）
Chain C 24–347（324 aa）
Chain C 455–502（48 aa）
Chain D 24–347（324 aa）
Chain D 455–502（48 aa）
Chain E 24–347（324 aa）
Chain E 455–502（48 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.80 Å
8CI2 human alpha7 nicotinic receptor in complex with the C4 nanobody under sub-saturating conditions Deposited 2023-02-08 Assembly 1 Other combination Heteromer；Protein × 8 PDB declaration: octameric（8） Consistent with protein count
Chain A 24–347（324 aa）
Chain A 455–502（48 aa）
Chain B 24–347（324 aa）
Chain B 455–502（48 aa）
Chain C 24–347（324 aa）
Chain C 455–502（48 aa）
Chain D 24–347（324 aa）
Chain D 455–502（48 aa）
Chain E 24–347（324 aa）
Chain E 455–502（48 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 4.40 Å
8F4V Alpha7 nicotinic acetylcholine receptor intracellular and transmembrane domains bound to ivermectin in a desensitized state Deposited 2022-11-11 Assembly 1 Protein homooligomer Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 231–496（266 aa） Fragment：Transmembrane domain and intracellular domain residues 231-496
Chain B 231–496（266 aa） Fragment：Transmembrane domain and intracellular domain residues 231-496
Chain C 231–496（266 aa） Fragment：Transmembrane domain and intracellular domain residues 231-496
Chain D 231–496（266 aa） Fragment：Transmembrane domain and intracellular domain residues 231-496
Chain E 231–496（266 aa） Fragment：Transmembrane domain and intracellular domain residues 231-496
Mutation：A263S, V268S, L270S, A474E Mutation：A263S, V268S, L270S, A474E Mutation：A263S, V268S, L270S, A474E Mutation：A263S, V268S, L270S, A474E Mutation：A263S, V268S, L270S, A474E IVM (2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-6'-[(2S)-butan-2-yl]-20,20b-dihydroxy-5',6,8,19-tetramethyl-17 -oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacy clooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside × 5 SOLUTION NMR
NMR measurement conditions pH 4.7；318 K；Ionic strength (raw mmCIF value) 25；Pressure 1
NMR sample composition 0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.22 mM [U-15N] V311C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 220 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.22 mM [U-15N] V311C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.22 mM [U-15N] C335-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 26 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 220 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.22 mM [U-15N] C335-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 26 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.2 mM [U-15N] C342-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 26 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 200 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.2 % [U-15N] C342-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 26 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.2 mM [U-15N] S350C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 200 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.2 mM [U-15N] S350C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.2 mM [U-15N] C375-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 200 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.2 mM [U-15N] C375-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 30 uM ivermectin, 0.1 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] C390-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 250 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] C390-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.24 mM [U-15N] L415C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 240 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.24 mM [U-15N] L415C-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.2 mM [U-15N] C435-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 22 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 200 uM ivermectin, 0.4 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.2 mM [U-15N] C435-MTSL alpha7nAChR TMD+ICD, 5 mM sodium acetate, 22 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.22 mM [U-13C; U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 30 uM ivermectin, 30 uM PNU, 0.2 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.22 mM [U-13C; U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 44 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 100 uM ivermectin, 0.3 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 250 uM ivermectin, 0.55 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 500 uM ivermectin, 0.95 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 500 uM ivermectin, 0.8 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 500 uM ivermectin, 0.8 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.25 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 500 uM ivermectin, 0.8 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
NMR sample composition 0.20 mM [U-15N] alpha7nAChR C317 TMD+ICD, 5 mM sodium acetate, 35 mM LDAO, 25 mM sodium chloride, 5 % D2O, 20 uM DSS, 500 uM ivermectin, 0.8 % DMSO, 95% H2O/5% D2O | 95% H2O/5% D2O
Resolution not provided
8P1H Crystal structure of the chimera of human 14-3-3 zeta and phosphorylated cytoplasmic loop fragment of the alpha7 acetylcholine receptor Deposited 2023-05-12 Assembly 1 Insufficient information Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count
Chain A 361–372（12 aa）
Chain B 361–372（12 aa）
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) EDO 1,2-ETHANEDIOL × 4 AZI AZIDE ION × 3 BEZ BENZOIC ACID × 1 PEG DI(HYDROXYETHYL)ETHER × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP；288 K；0.2 M Magnesium acetate tetrahydrate; 0.1 M Sodium cacodylate trihydrate pH 6.5; 20% w/v Polyethylene glycol 8,000
Resolution 1.95 Å R-free 0.253
8UT1 Alpha7-nicotinic acetylcholine receptor bound to epibatidine Deposited 2023-10-30 Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded CA CALCIUM ION × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 15 9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5 EPJ EPIBATIDINE × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.30 Å
8UTB Alpha7-nicotinic acetylcholine receptor bound to epibatidine and NS-1738 Deposited 2023-10-30 Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded XG3 N-(5-chloro-2-hydroxyphenyl)-N'-[2-chloro-5-(trifluoromethyl)phenyl]urea × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 EPJ EPIBATIDINE × 5 9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5 POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.30 Å
8UZJ Alpha7-nicotinic acetylcholine receptor bound to epibatidine and ivermectin Deposited 2023-11-15 Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded CA CALCIUM ION × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5 EPJ EPIBATIDINE × 5 IVM (2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-6'-[(2S)-butan-2-yl]-20,20b-dihydroxy-5',6,8,19-tetramethyl-17 -oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacy clooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside × 5 POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.30 Å
8V80 Alpha7-nicotinic acetylcholine receptor bound to epibatidine and (-)-TQS Deposited 2023-12-04 Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded CA CALCIUM ION × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 10 9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5 EPJ EPIBATIDINE × 5 YLR (3aR,4S,9bS)-4-(naphthalen-1-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.34 Å
8V82 Alpha7-nicotinic acetylcholine receptor bound to epibatidine and PNU-120596 Deposited 2023-12-04 Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded CA CALCIUM ION × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 15 9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5 EPJ EPIBATIDINE × 5 I34 N-(5-Chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.61 Å
8V86 Alpha7-nicotinic acetylcholine receptor bound to GAT107 Deposited 2023-12-04 Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 10 9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 YLI (3aR,4S,9bS)-4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.47 Å
8V88 Alpha7-nicotinic acetylcholine receptor bound to epibatidine and GAT107 Deposited 2023-12-05 Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded CA CALCIUM ION × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 10 9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5 EPJ EPIBATIDINE × 5 YLI (3aR,4S,9bS)-4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.30 Å
8V89 Alpha7-nicotinic acetylcholine receptor time resolved resting state Deposited 2023-12-05 Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 R16 HEXADECANE × 5 9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5 POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.53 Å
8V8A Alpha7-nicotinic acetylcholine receptor time resolved bound to epibatidine and PNU-120596 desensitized intermediate state Deposited 2023-12-05 Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded CA CALCIUM ION × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 15 9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5 EPJ EPIBATIDINE × 5 I34 N-(5-Chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.19 Å
8V8C Alpha7-nicotinic acetylcholine receptor time resolved bound to epibatidine and PNU-120596 asymmetric state 1 Deposited 2023-12-05 Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 EPJ EPIBATIDINE × 5 I34 N-(5-Chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea × 5 CA CALCIUM ION × 3 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.29 Å
8V8D Alpha7-nicotinic acetylcholine receptor time resolved bound to epibatidine and PNU-120596 asymmetric state 2 Deposited 2023-12-05 Assembly 1 Insufficient information Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 24–412（389 aa）
Chain A 413–502（90 aa）
Chain B 24–412（389 aa）
Chain B 413–502（90 aa）
Chain C 24–412（389 aa）
Chain C 413–502（90 aa）
Chain D 24–412（389 aa）
Chain D 413–502（90 aa）
Chain E 24–412（389 aa）
Chain E 413–502（90 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 EPJ EPIBATIDINE × 5 I34 N-(5-Chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea × 5 CA CALCIUM ION × 3 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.31 Å
9IIR human alpha 7 nicotinic acetylcholine receptor in complex with GAT107 and calcium (desensitized state) Deposited 2024-06-21 Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded YLI (3aR,4S,9bS)-4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide × 5 CA CALCIUM ION × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 CLR CHOLESTEROL × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.93 Å
9IIV human alpha 7 nicotinic acetylcholine receptor in complex with GAT107 and calcium (open state) Deposited 2024-06-21 Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 CA CALCIUM ION × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.89 Å
9J37 Cryo-EM structure of human Alpha-7 nicotinic acetylcholine receptor Deposited 2024-08-08 Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 23–502（480 aa）
Chain B 23–502（480 aa）
Chain C 23–502（480 aa）
Chain D 23–502（480 aa）
Chain E 23–502（480 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 CLR CHOLESTEROL × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.5
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.30 Å
9LH5 human alpha 7 nicotinic acetylcholine receptor in complex with L-nicotine (open state) Deposited 2025-01-11 Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.61 Å
9LH6 human alpha 7 nicotinic acetylcholine receptor in complex with L-nicotine (five-nicotine-bound desensitized state) Deposited 2025-01-11 Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.69 Å
9LH8 human alpha 7 nicotinic acetylcholine receptor in complex with L-nicotine (four-nicotine-bound desensitized state) Deposited 2025-01-11 Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 4 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.74 Å
9LH9 human alpha 7 nicotinic acetylcholine receptor in complex with L-nicotine (ortho-three-nicotine-bound desensitized state) Deposited 2025-01-11 Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.98 Å
9LHA human alpha 7 nicotinic acetylcholine receptor in complex with L-nicotine (meta-three-nicotine-bound desensitized state) Deposited 2025-01-11 Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 3 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.96 Å
9LHB human alpha 7 nicotinic acetylcholine receptor in complex with L-nicotine (ortho-two-nicotine-bound desensitized state) Deposited 2025-01-11 Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 2 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.11 Å
9LHC human alpha 7 nicotinic acetylcholine receptor in complex with L-nicotine (meta-two-nicotine-bound desensitized state) Deposited 2025-01-11 Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 2 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.17 Å
9LHD human alpha 7 nicotinic acetylcholine receptor in complex with L-nicotine (one-nicotine-bound desensitized state) Deposited 2025-01-11 Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 1 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.24 Å
9LHE human alpha 7 nicotinic acetylcholine receptor in complex with L-nicotine (nicotine-free desensitized state) Deposited 2025-01-11 Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.25 Å
9LN7 Alpha-7 nicotinic acetylcholine receptor bound to inhibitory bicyclic peptide KP2007 in a resting state. Deposited 2025-01-20 Assembly 1 Other combination Heteromer；Protein × 10 PDB declaration: decameric（10） Consistent with protein count
Chain A 1–502（502 aa）
Chain C 1–502（502 aa）
Chain E 1–502（502 aa）
Chain G 1–502（502 aa）
Chain I 1–502（502 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.94 Å
9NX0 Alpha7-nicotinic acetylcholine receptor bound to conotoxin ImI Deposited 2025-03-25 Assembly 1 Other combination Heteromer；Protein × 10 PDB declaration: decameric（10） Consistent with protein count
Chain A 24–501（478 aa）
Chain B 24–501（478 aa）
Chain C 24–501（478 aa）
Chain D 24–501（478 aa）
Chain E 24–501（478 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.06 Å
9NX1 Alpha7-nicotinic acetylcholine receptor bound to conotoxin ImII Deposited 2025-03-25 Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric（6） Consistent with protein count
Chain B 24–501（478 aa）
Chain C 24–501（478 aa）
Chain D 24–501（478 aa）
Chain E 24–501（478 aa）
Chain F 24–501（478 aa）
Not recorded NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10 EPJ EPIBATIDINE × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 7.4
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.10 Å
9QTN Human alpha7 nicotinic receptor in complex with the F1 nanobody Deposited 2025-04-09 Assembly 1 Other combination Heteromer；Protein × 10 PDB declaration: decameric（10） Consistent with protein count
Chain A 24–502（479 aa）
Chain B 24–502（479 aa）
Chain C 24–502（479 aa）
Chain D 24–502（479 aa）
Chain E 24–502（479 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.28 Å
9QTO Human alpha7 nicotinic receptor in complex with the E6 nanobody Deposited 2025-04-09 Assembly 1 Insufficient information Heteromer；Protein × 10 PDB declaration: decameric（10） Consistent with protein count
Chain A 24–349（326 aa）
Chain B 24–349（326 aa）
Chain C 24–349（326 aa）
Chain D 24–349（326 aa）
Chain E 24–349（326 aa）
Not recorded No recorded non-water small molecule ELECTRON MICROSCOPY
cryo-EM buffer pH 7.8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 2.16 Å
9VIQ human alpha 7 nicotinic acetylcholine receptor L277A mutant in complex with L-nicotine (desensitized state) Deposited 2025-06-19 Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Mutation：L277A Mutation：L277A Mutation：L277A Mutation：L277A Mutation：L277A NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.24 Å
9VIX human alpha 7 nicotinic acetylcholine receptor L278A mutant in complex with L-nicotine (desensitized state) Deposited 2025-06-19 Assembly 1 Other combination Homooligomer；Protein × 5 PDB declaration: pentameric（5） Consistent with protein count
Chain A 1–502（502 aa）
Chain B 1–502（502 aa）
Chain C 1–502（502 aa）
Chain D 1–502（502 aa）
Chain E 1–502（502 aa）
Mutation：L278A Mutation：L278A Mutation：L278A Mutation：L278A Mutation：L278A NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 5 NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 ELECTRON MICROSCOPY
cryo-EM buffer pH 8
cryo-EM vitrification conditions Cryogen ETHANE
Resolution 3.06 Å

This page presents structural evidence recorded in PDB/mmCIF.“No recorded non-water small molecule” does not prove that the experimental sample was ligand-free; experimental conditions belong to the PDB experiment, while ligands and copy counts are shown for each biological assembly.